Close Menu

NEW YORK – NeuMoDx announced Monday its multiplex RT-PCR SARS-CoV-2 test received CE marking.

The NeuMoDx SARS-CoV-2 Assay detects SARS-CoV-2 RNA from the Nsp2 gene and N gene in nasopharyngeal, oropharyngeal, or nasal swab specimens. The test runs on the NeuMoDx 288 and 96 Molecular Systems with results in 80 minutes from primary collection or daughter tubes, the company said. The systems can run up to 288 patient samples and can be used by laboratories to validate their own laboratory-developed tests, NeuMoDx added. 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.

Oct
09
Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.